Most
cancer deaths are caused by
metastasis. The
phosphocreatine 3-
kinase (PI3K) family includes the I-III classes, with class I divided into 4 subtypes (alpha, ß, γ, delta); and PI3K signaling participates in the regulatory processes of cell proliferation, differentiation, apoptosis, and
glucose transport. Moreover, PI3Ks are modulators of cellular
membrane lipids involved in signaling and trafficking events. The PI3Kdelta
isoform (PI3Kdelta), which is not only specifically expressed in hematopoietic cells, but also in different tumor cell lines, is expressed extensively. The increase in PI3Kdelta activity is often associated with a variety of
cancers. Currently, the strategy of
tumor therapy based on PI3Kd and its related signaling pathway is developing. Besides its established role in controlling functions in autoimmunity and
inflammation, the role of PI3Kdelta in
tumor and
metastasis is not clearly elucidated, with the effects of inhibiting PI3Kdelta in several types of
tumors also remaining unexplored. In addition, the specific inhibitor of PI3Kdelta in
tumor progression and
metastasis and its underlying mechanism need to be further studied. The purpose of this review is to rationalize the existing functions and mechanisms of PI3Kdelta in
tumor metastasis and the relationship with hematopoietic cells in
cancers as well cross-talking with
miRNA, which provides a new theoretical basis and potential therapeutic target for the
drug therapy of
tumor metastasis.